{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:02:41Z","timestamp":1756425761560,"version":"3.44.0"},"reference-count":19,"publisher":"BMJ","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DTB"],"published-print":{"date-parts":[[2012,11]]},"abstract":"<jats:p>\n                  <jats:bold>\n                     <jats:italic>Clostridium difficile<\/jats:italic>\n                  <\/jats:bold> infection (CDI), also known as <jats:bold>\n                     <jats:italic>C. difficile<\/jats:italic>\n                  <\/jats:bold>-associated disease or diarrhoea (CDAD), is an important cause of hospital-acquired diarrhoea with disease severity ranging from mild diarrhoea to fulminant colitis.<jats:sup>1,2<\/jats:sup> In\u00a0addition, over 40% of new cases of CDI occur outside hospital.<jats:sup>3,4<\/jats:sup> \u25bc Fidaxomicin (Dificlir \u2013 Astellas), the first antibiotic in a new class called macrocyclics, has recently been licensed for the treatment of <jats:bold>\n                     <jats:italic>C. difficile<\/jats:italic>\n                  <\/jats:bold> infection in adults.<jats:sup>5<\/jats:sup> Here we provide a brief overview of <jats:bold>\n                     <jats:italic>C. difficile<\/jats:italic>\n                  <\/jats:bold> infection and assess how fidaxomicin fits with current management strategies for treatment of such infections. <\/jats:p>","DOI":"10.1136\/dtb.2012.11.0142","type":"journal-article","created":{"date-parts":[[2012,11,15]],"date-time":"2012-11-15T07:43:56Z","timestamp":1352965436000},"page":"130-132","source":"Crossref","is-referenced-by-count":1,"title":["\u25bc Fidaxomicin for the treatment of <i>Clostridium difficile<\/i> infections"],"prefix":"10.1136","volume":"50","member":"239","published-online":{"date-parts":[[2012,11,15]]},"reference":[{"key":"2025082723455889000_50.11.130.1","unstructured":"National Institute for Health and Clinical Excellence, 2012. Evidence summary: new medicine. Clostridium difficile infection: fidaxomicin [online]. Available: http:\/\/publications.nice.org.uk\/clostridium-difficile-infection-fidaxomicin-esnm1 [Accessed 24 October 2012]."},{"key":"2025082723455889000_50.11.130.2","unstructured":"European Medicines Agency, 2011. European public assessment report. Dificlir. [online]. Available: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002087\/WC500119707.pdf [Accessed 24 October 2012]."},{"key":"2025082723455889000_50.11.130.3","doi-asserted-by":"crossref","unstructured":"C. difficile outside hospital. DTB 2009; 47: 133.","DOI":"10.1136\/dtb.2009.11.0050"},{"key":"2025082723455889000_50.11.130.4","unstructured":"Department of Health, Health Protection Agency, 2008. Clostridium difficile infection: how to deal with the problem [online]. Available: http:\/\/www.dh.gov.uk\/en\/Publicationsandstatistics\/Publications\/PublicationsPolicyAndGuidance\/DH_093220 [Accessed 24 October 2012]."},{"key":"2025082723455889000_50.11.130.5","unstructured":"Dificlir 200mg film-coated tablets. Summary of product characteristics, UK. Astellas Pharma Ltd, March 2012."},{"key":"2025082723455889000_50.11.130.6","unstructured":"Health Protection Agency, 2012. Clostridium difficile [online]. Available: http:\/\/www.hpa.org.uk\/Topics\/InfectiousDiseases\/InfectionsAZ\/ClostridiumDifficile\/GeneralInformation\/ [Accessed 24 October 2012]."},{"key":"2025082723455889000_50.11.130.7","doi-asserted-by":"crossref","unstructured":"Yearsley KA Proton pump inhibitor therapy is a risk factor for Clostridium difficile-associated diarrhoea. Aliment Pharmacol Ther 2006; 24: 613-9.","DOI":"10.1111\/j.1365-2036.2006.03015.x"},{"key":"2025082723455889000_50.11.130.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1012413"},{"key":"2025082723455889000_50.11.130.9","unstructured":"Health Protection Agency, 2012. Summary points on Clostridium difficile infection (CDI) [online]. Available: http:\/\/www.hpa.org.uk\/webc\/HPAwebFile\/HPAweb_C\/1278944283388 [Accessed 24 October 2012]."},{"key":"2025082723455889000_50.11.130.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhin.2012.02.004"},{"key":"2025082723455889000_50.11.130.11","unstructured":"Hassoun A , 2012. Clostridium difficile-associated disease [online]. Available: http:\/\/bestpractice.bmj.com\/best-practice\/monograph\/230.html [Accessed 24 October 2012]."},{"key":"2025082723455889000_50.11.130.12","doi-asserted-by":"crossref","unstructured":"Nelson RL Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst Rev 2011; 9: CD004610. DOI:10.1002\/14651858.CD004610.pub4 [Last assessed as up-to-date 12 October 2010].","DOI":"10.1002\/14651858.CD004610.pub4"},{"key":"2025082723455889000_50.11.130.13","doi-asserted-by":"publisher","DOI":"10.1099\/mic.0.042010-0"},{"key":"2025082723455889000_50.11.130.14","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis440"},{"key":"2025082723455889000_50.11.130.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0910812"},{"key":"2025082723455889000_50.11.130.16","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(11)70374-7"},{"key":"2025082723455889000_50.11.130.17","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir404"},{"key":"2025082723455889000_50.11.130.18","unstructured":"Scottish Medicines Consortium, 2012. Fidaxomicin 200mg film-coated tablets (Dificlir): SMC No. (791\/12) [online]. Available: http:\/\/www.scottishmedicines.org.uk\/files\/advice\/fidaxomicin_Dificlir_FINAL_June_2012_for_website.pdf [Accessed 24 October 2012]."},{"key":"2025082723455889000_50.11.130.19","unstructured":"All Wales Medicines Strategy Group, 2012. AWMSG appraisal work programme [online]. Available: http:\/\/www.wales.nhs.uk\/sites3\/Documents\/371\/AWMSG%20Appraisal%20Work%20Programme.pdf [Accessed 24 October 2012]."}],"container-title":["Drug and Therapeutics Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/dtb.2012.11.0142","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T06:46:09Z","timestamp":1756363569000},"score":1,"resource":{"primary":{"URL":"https:\/\/dtb.bmj.com\/lookup\/doi\/10.1136\/dtb.2012.11.0142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":19,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2012,11,15]]},"published-print":{"date-parts":[[2012,11]]}},"alternative-id":["10.1136\/dtb.2012.11.0142"],"URL":"https:\/\/doi.org\/10.1136\/dtb.2012.11.0142","relation":{},"ISSN":["0012-6543","1755-5248"],"issn-type":[{"type":"print","value":"0012-6543"},{"type":"electronic","value":"1755-5248"}],"subject":[],"published":{"date-parts":[[2012,11]]}}}